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Background: Bacterial conversion of ginsenosides is crucial for the health-promoting effects of ginsenosides.
Previous studies on the biotransformation of ginsenoside Rb1 (Rb1) by gut bacteria have focused on the
ginsenoside Rd (Rd) pathway (Rb1→ Rd→ ginsenoside F2 (F2)→ compound K (Cpd K)). This study aims to
examine the gypenoside pathway in human gut bacteria in vitro.
Methods: The metabolic pathways of ginsenoside Rb1 and its metabolites ginsenoside Rd and gypenoside XVII in
human gut bacteria were investigated by incubating the compounds anaerobically with pooled or individual gut
bacteria samples from healthy volunteers. Ginsenoside Rb1, the metabolites generated by human gut bacteria, and
degraded products in simulated gastric fluid (SGF) were qualitatively analyzed using an LC/MSD Trap system in the
negative ion mode and quantitatively determined by HPLC-UV analysis.
Results: When incubated anaerobically with pooled gut bacteria, Rb1 generated five metabolites, namely Rd, F2,
Cpd K, and the rare gypenosides XVII (G-XVII) and LXXV (G-LXXV). The gypenoside pathway (Rb1→ G-XVII
→ G-LXXV→ Cpd K) was rapid, intermediate, and minor, and finally converted Rb1 to Cpd K via G-XVII→ F2
(major)/G-LXXV (minor). Both the Rd and gypenoside pathways exhibited great inter-individual variations in age-and
sex-independent manners (P > 0.05). Rb1 was highly acid-labile and degraded rapidly to form F2, ginsenoside Rg3,
ginsenoside Rh2, and Cpd K, but did not generate the gypenosides in SGF. The formation of the gypenosides might
be explained by the involvement of a gut bacteria-mediated enzymatic process.
Conclusions: Rb1 was metabolized to G-XVII, F2 (major) or G-LXXL (minor), and finally Cpd K by human gut bacteria
in vitro.Background
Ginsenosides are the major bioactive components in
Panax, including Panax ginseng, Panax quinquefolium,
and Panax notoginseng [1], which are the most popular
herbs used for medicinal and nutritional purposes in
China, Japan, Korea, and some Western countries. Two
dammarane-type triterpene O-glycosides, namely 20(S)-
protopanaxadiol (PPD) and 20(S)-protopanaxatriol, are the
major ginsenosides in different parts of Panax, including
the flower bud, berry, crown, rootlet, side root, seed bud,
seed, stem, and leaf [2,3], and their differently processed
herbal products [4]. As one of the most important PPD-
type ginsenosides, ginsenoside Rb1 (Rb1) has exhibited* Correspondence: ruyan@umac.mo
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reproduction in any medium, provided the orvarious pharmacological activities, including neuroprotec-
tive, antitumor, cardiovascular-protective, and anti-aging
effects, in many in vitro and in vivo models [5-7].
The intestinal absorption of glycosides in plants or
foods is poor, while their metabolites generated by intes-
tinal microflora are more permeable and bioactive [8-11].
The oral bioavailability of PPD-type ginsenosides is gener-
ally low (<10%) [12]. The bacterial metabolites are the
main forms transported across the epithelial membrane
and are most likely to be the real in vivo active forms [13].
This finding has led to research on microbial metabolism
and the pharmacological activities of the resultant metabo-
lites of ginsenosides including Rb1 [14-16]. Hasegawa et al.
[17] proposed metabolism of Rb1 via the ginsenoside Rd
(Rd) pathway by human intestinal bacteria in vitro, which
was initiated at the C-20 glucose (Rb1→ Rd→ ginsenoside
F2 (F2)→Compound K (Cpd K)), and the gypenoside
XVII (G-XVII) pathway, which was initiated by removal ofd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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LXXV)→Cpd K). However, the gypenoside pathway of
Rb1 was only speculated from the results of TLC, and the
data were not provided by the authors [18,19].
The formation of G-XVII from Rb1 has been investi-
gated in several metabolic studies with individual fungal
strains [20-22]. Moreover, G-XVII was detected in vivo
in rats receiving oral administration of Rb1 [23,24]. Al-
though there are no reports on the formation of G-LXXV
in rats, the presence of G-XVII suggests the existence of
both the gypenoside and Rd pathways of Rb1 metabolism
in rats. In plasma and urine samples from healthy subjects
who received oral administration of a ginseng extract, only
Rd and Cpd K were detected [25,26]. The gypenoside
pathway of Rb1 metabolism in the human body remains
to be confirmed.
Ginsenoside Rd and Cpd K have been shown to pos-
sess potent pharmacological activities [27], contributing
to the beneficial effects of Rb1. The available, albeit limited,
reports on the bioactivities of gypenosides have described
that the gypenosides from Gynostemma pentaphyllum
have anticancer, antioxidative, and antihyperlipidemic ef-
fects [28,29]. It is important to know whether gypenosides
can be formed from ginsenoside Rb1 by bacterial biotrans-
formation in the human gut lumen.
Gypenosides could be generated from ginsenoside Rb1
via a non-enzymatic process in vivo, such as degradation
in the acidic environment of the stomach [30], other
than biotransformation by gut bacteria. Several studies
have reported the degradation of several ginsenosides,
including Rb1, in acidic environment [31,32]. However,
the aspect of whether Rb1 is degraded to form gypeno-
sides remains unclear.
This study aims to examine the gypenoside pathway in
human gut bacteria in vitro. The biotransformation of
Rb1 by human gut bacteria was characterized by high-
performance liquid chromatography with a UV detector
(HPLC-UV) and HPLC-mass spectrometry (MS) analyses.
The gypenoside pathway of Rb1 was investigated and
compared with the Rd pathway by incubating Rb1, Rd,
and G-XVII separately with pooled human gut bacterial
samples. The inter-individual variations in the G-XVII and
Rd pathways were also characterized with gut bacterial
samples from 58 individuals of both sexes and different
ages. The stabilities of Rb1 and Rd in simulated gastric
fluid (SGF) were examined to rule out the generation of
these gypenosides under the acidic gastric environment.
Methods
Chemicals, reagents, and materials
Ginsenoside Rb1, Rd, F2, Rg3, Cpd K, Rh2, G-XVII, and
Rg1 were supplied by Chengdu Must Biotechnology Co.
Ltd. (Chengdu, China). The purity was >98% (HPLC-
UV). The BBL™ Brain Heart Infusion (BHI) medium,GasPak™ EZ anaerobe container system with an indica-
tor, and GasPak™ EZ large incubation container were
purchased from Becton Dickinson (Franklin Lakes, NJ,
USA). L-cystine was purchased from Research Organics
Inc. (Cleveland, OH, USA). Dimethyl sulfoxide (DMSO),
bovine hemin, and vitamin K1 were supplied by Sigma-
Aldrich (St. Louis, MO, USA). Methanol, 1-butanol, and
acetonitrile were HPLC-grade and purchased from Merck
(Darmstadt, Germany). Dulbecco’s phosphate-buffered sa-
line (PBS) was provided by Life Technologies (Carlsbad,
CA, USA). Hydrochloric acid and sodium carbonate
(analytical grade) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Deionized water was prepared
in-house using a Milli-Q purification system (Millipore,
Bedford, MA, USA).
Instrumentation and analytical conditions
Chromatographic separation was performed on an Agi-
lent 1200 Series HPLC apparatus (Agilent Technologies,
Santa Clara, CA, USA) equipped with a vacuum degasser,
a binary pump, and an autosampler, and connected to a
diode array detector (DAD). Samples were loaded onto an
Alltima C18 column (250 × 4.6 mm, 5 μm). The column
temperature was maintained at 25°C. The mobile phase
consisted of water (A) and acetonitrile (B) and flowed at
1.5 mL/min. The following gradient elution program was
used for samples obtained from bacterial incubations: 0-
10 min, 19-20% B; 10-28 min, 20-30% B; 28-40 min, 30-
60% B; 40-48 min, 60-100% B. The elution program was
modified when the incubations of ginsenosides with SGF
were analyzed as follows: 0-10 min, 19-20% B; 10-28 min,
20-30% B; 28-35 min, 30-60% B; 35-45 min, 60-100% B.
Rb1 and its bacterial metabolites were monitored at
203.4 nm and their UV absorbance was recorded over
200-400 nm. The injection volume was 5 μL.
MS analysis was performed on an liquid chromato-
graph/mass selective detector (LC/MSD) Trap system
(Agilent Technologies, Palo Alto, CA, USA) equipped
with an ion-trap mass spectrometer with an electrospray
ionization (ESI) interface. Agilent ChemStation for LC
3D System software (Rev. B. 01. 03-SR2) (Agilent Tech-
nologies, Santa Clara, CA, USA) was used for instru-
ment control, data acquisition, and data management.
Except for replacement of the water with 50 mM am-
monium acetate in water, the mobile phase composition
and gradient elution program were the same as those
for the above HPLC analysis method for human gut bac-
teria samples. The mass spectrometer was operated in
the negative ion mode with the following conditions:
drying gas (N2), 8 L/min; temperature, 325°C; nebulizer
pressure, 30 psi; scan range, m/z 100-1400. The ESI-
MS/MS conditions were as follows: negative ion mode;
separation width, 4; fragment amplification, 1.0 V; scan
range, m/z 100-1400.
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The medium was prepared according to our previous re-
port [33]. Briefly, 100 mL of autoclaved BHI medium
(3.7 g/100 mL) was supplemented with 0.05 mg of vitamin
K1, 0.5 mg of bovine hemin, and 50 mg of L-cystine. The
fecal samples (healthy Chinese, 18-92 years old) were pro-
vided by Kiang Wu Hospital and the experimental proto-
col is approved by Kiang Wu Hospital and University of
Macau before conduct. Human gut bacteria suspensions
were prepared at 4°C according to our previous report
[33] with minor modifications. Fecal samples were freshly
collected and pooled at 1 g each for identification of Rb1
metabolic pathways, or individually processed at 5 g each
for characterization of individual variations in Rb1 metab-
olism. The individual or pooled fecal samples were mixed
with 20 mL of BHI medium and the resulting suspensions
were centrifuged at 200 × g for 5 min. The supernatants
were then centrifuged at 5000 × g for 30 min. The human
gut bacteria suspensions were obtained by resuspension of
the bacterial precipitates in 5 mL of BHI medium.
Biotransformation of Rb1 by human gut bacteria
Biotransformation assays of Rb1 were conducted with
pooled or individual human gut bacteria samples to
examine the existence of the gypenoside pathway and
compare it with the Rd pathway. A high concentration
of Rb1 was used to capture the minor formation and
quantitative variations in the metabolites formed from
the minor gypenoside pathway based on the great indi-
vidual variations in gut bacteria compositions and meta-
bolic capabilities [34]. The anaerobic incubation system
contained 250 μL of gut bacteria suspension, 100 μL of
Rb1 in DMSO (final concentration, 100 mM Rb1), and
4.75 mL of BHI medium. The incubation system was
maintained in an anaerobic state at 37°C using the Gas-
Pak™ EZ anaerobe container system.
The metabolic pathway and time-course of Rb1 me-
tabolism by human gut bacteria were characterized in
five independent experiments using pooled samples. In
each experiment, the reaction of Rb1 with a human gut
bacteria suspension was conducted in duplicate. Control
reactions were conducted in parallel by adding 250 μL of
PBS (pH 7.0) instead of gut bacteria suspension. The reac-
tions were terminated at 0, 2, 4, 12, 18, 24, 36, and 48 h,
respectively, by adding 15 mL of 1-butanol followed by
immediate centrifugation at 5000 × g for 30 min to remove
the bacteria. The resulting supernatants were mixed with
100 μL of ginsenoside Rg1 (final concentration, 100 mM)
as an internal standard (IS), and each mixture was ex-
tracted twice with water-saturated 1-butanol. The organic
layers were combined and dried by rotary evaporation
(BUCHI, Flavil, Switzerland). The residue was reconsti-
tuted in 0.2 mL of methanol, and an aliquot (5 μL) was
subjected to HPLC-UV or HPLC-MS analysis.Inter-individual variations in the gypenoside and Rd
pathways were investigated by incubating Rb1 with gut
bacteria suspensions from different individuals under the
same conditions described above, and the incubated
samples collected at 18 h were processed as described
above. Samples were analyzed by HPLC-UV, and the
peak area ratio data of each analyte were collected for
comparison.
Biotransformation of Rd and G-XVII by human gut
bacteria
The metabolism of the two positional isomers Rd and
G-XVII by human gut bacteria was investigated by incu-
bation with the same human gut bacteria sample in par-
allel to identify the pathways between Rd/G-XVII and
Cpd K. The anaerobic incubation system contained
20 μL of gut bacteria suspension, 10 μL of ginsenoside
Rd or G-XVII (final concentration, 100 μM Rd or G-
XVII), and 170 μL of BHI medium. The concentrations
of Rd and G-XVII were determined based on the high
amounts of all metabolites determined from a prelimin-
ary study. Each reaction was conducted in triplicate.
Control reactions without gut bacteria were conducted
in parallel.
Reactions were terminated at 0, 2, 4, 6, 8, 12, 18, 24,
36, and 48 h, respectively, by adding 1.2 mL of 1-butanol
followed by centrifugation at 5000 × g for 30 min to re-
move the bacteria. After adding 10 μL of ginsenoside
Rg1 (final concentration, 100 μM Rg1) as an internal
standard, the resulting mixture was processed in the
same manner described above before being subjected to
HPLC-UV analysis.
Stabilities of Rb1 and Rd in SGF
SGF was prepared by diluting 3.84 mL of hydrochloric
acid to 1000 mL with deionized water (pH 1.2) accord-
ing to the Chinese Pharmacopoeia [35]. Ten microliters
of ginsenoside Rb1 or Rd in DMSO (final concentration,
71.4 μM) was mixed with 200 μL of SGF, and kept at
37°C for different time intervals (0, 20, 40, 60, 90, 150,
180 and 300 min) before adding 70 μL of 0.1 mol/L
Na2CO3 to examine the acidic stability. Each reaction
was conducted in triplicate. The mixture was shaken for
1 min by vortexing and centrifuged at 14,000 × g for
5 min. The upper layer was decanted and an aliquot
(20 μL) was subjected to HPLC-UV analysis.
Calibration curves of Rb1 and its metabolites Rd, F2,
G-XVII, and Cpd K in human gut bacteria
Serial concentrations of Rb1, Rd, G-XVII, F2, and Cpd K
were prepared in DMSO, and mixed with a pooled hu-
man gut bacteria suspension and BHI medium as de-
scribed in the section entitled Biotransformation of Rb1
by Human Gut Bacteria. The resulting mixtures were
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(5000 × g, 30 min). The organic layers were processed in
the same manner described above and then subjected to
HPLC-UV analysis. Calibration curves were constructed
by plotting the peak area ratio of each analyte to the IS
(Y) as a function of the analyte concentration (X) in the
reaction system.
For measurements of the intra-day precision and accur-
acy, three concentration levels for each standard (low,
medium, and high) were prepared as quality control (QC)
samples and analyzed on the same day. The inter-dayFigure 1 HPLC-UV chromatograms of (A) mixed ginsenoside standard
and intestinal bacteria from (C) a 65-year-old male, (D) a 44-year-old
gypenoside XVII; M3, ginsenoside F2; M4, gypenoside LXXV; M5, compoundprecision and accuracy were determined with the same
three QC samples on three consecutive days.
Calibration curves of ginsenosides in SGF
A mixed stock solution of Rb1, Rd, G-XVII, F2, Rg3,
Cpd K, and Rh2 was prepared in DMSO. A series of
working solutions were prepared with DMSO using dilu-
tion factors of 2.5, 5, 10, 20, 40, and 80 from the stock
solution. An aliquot (10 μL) of each working solution
was spiked with 200 μL of SGF and processed with
70 μL of 0.1 mol/L Na2CO3 as described above. Thes, and incubated samples of Rb1 with (B) pooled gut bacteria
male, and (E) a 54-year-old female. M1, ginsenoside Rd; M2,
K.
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calibration curve was obtained by plotting the peak area
of each analyte (Y) against its concentration in SGF (X).Data analysis
Data were presented as the means ± standard deviation
(SD) of triplicate analyses (experiments with pooled
human gut bacteria or SGF) or individual measurements
(experiments on inter-individual variations). Sex and age
differences in ginsenoside Rb1 metabolism were com-
pared by Student’s t-test. Values of P < 0.05 were consid-
ered statistically significant.Results
Metabolism of ginsenoside Rb1 by pooled human gut
bacteria
Fecal samples from 50 healthy volunteers (25 males and
25 females, range, 45.7-73.7 years) were collected and
pooled at 10 individuals each to prepare five human gut
bacteria pools. When Rb1 was incubated with pooled
human gut bacteria, five peaks (M1-M5) were observed
at 35.1, 35.6, 38.2, 39.7, and 44.4 min, respectively, which
were absent in control reactions (Figure 1). Under the de-
veloped analytical conditions, Rb1 and its metabolites
were well-separated from the endogenous interferences of
the in vitro anaerobic incubation system. The retention
times and characteristic CID fragment ions of the ginse-
noside standards and Rb1 metabolites are summarized in
Table 1.
Rb1 was eluted at 33.2 min and showed its pseudo-
molecular ion at m/z 1107 ([M-H]-) and chloride adduct
ion at m/z 1143 ([M + Cl]-), corresponding to a molecu-
lar weight of 1108 Daltons. The fragment ions at m/z
945 ([M-H2O-H]
-), m/z 783 ([M-2H2O-H]
-), and m/z
621 ([M-3H2O-H]
-) in the CID spectrum corresponded
to loss of one, two, and three glucose molecules from
Rb1, respectively.Table 1 HPLC-ESI-MS and corresponding CID data of ginseno
human gut bacteria
Retention time (min) MS (m/z)
[M-H]- [M + Cl]- [M + AcO]-
20.9 799 835 859 637[
33.2 1107 1143 - 94
35.1 945 981 -
35.6 945 981 -
38.2 783 819 843
39.7 783 819 843
40.3 783 819 -
45.4 621 657 681
44.4 621 657 681The retention times and mass spectral profiles of M1
(35.1 min), M3 (38.2 min), and M5 (44.4 min) were identi-
cal to those of Rd, F2, and Cpd K, respectively. The reten-
tion time and mass spectral profile of M2 (35.6 min) were
identical to those of G-XVII, which was formed from Rb1
by hydrolytic removal of one glucose molecule from the
C-3 position of Rb1. Thus, M1–M3 and M5 were unam-
biguously identified as ginsenosides Rd, G-XVII, F2, and
Cpd K, respectively.
M4 was eluted at 39.7 min. The MS spectral profile of
M4 was similar to those of M3 (ginsenoside F2) and gin-
senoside Rg3 (Table 1), supporting that M4 contained a
ginsenoside glycoside with two glucoses. However, the
retention time of M4 was different from that of either
ginsenoside Rg3 (40.3 min, with two glucoses at the C-3
position) or F2 (38.2 min, with one glucose at the C-3
position and another at the C-20 position) (Figure 1).
Thus, M4 was tentatively identified as G-LXXV, a me-
tabolite formed from Rb1 with two glucose molecules
remaining at the C-20 position.
Taken together, Rb1 biotransformation by human gut
bacteria in vitro resulted in the formations of gypeno-
sides as well as metabolites of the Rd pathway.
Time-course of Rb1 metabolism by human gut bacteria
The calibration curves of Rb1, Rd, F2, G-XVII, and Cpd
K in the in vitro anaerobic incubation system showed
good linearity (r2 > 0.998, P < 0.001) over the concentra-
tion ranges tested (Table 2). The overall intra-day and
inter-day variations were less than 6%, and recovery was
higher than 85% (except for ~60% for 10 μM Cpd K)
(Additional file 1: Table S1).
When Rb1 was incubated with the pooled human gut
bacteria (Figure 2A), Rb1 was rapidly eliminated by the
human gut bacteria and less than 20% of the Rb1 remained
intact at 12 h. The metabolites from the Rd pathway, Rd
and F2, appeared in the incubations in turn, with Rd reach-
ing its maximum at 12 h (representing ~50% of the initialside standards and the metabolites of ginsenoside Rb1 by
CID (m/z) Identity
M-H-Glc]-, 619[M-H-Glc-H2O]-, 475[M-H-2Glc]- Ginsenoside Rg1 (IS)
5[M-H-Glc]-, 783[M-H-2Glc]-, 621[M-H-3Glc]- Ginsenoside Rb1
783[M-H-Glc]-, 621[M-H-2Glc]-, Ginsenoside Rd (M1)
783[M-H-Glc]-, 621[M-H-2Glc]-, Gypenoside XVII (M2)
621[M-H-Glc]-, 459[M-H-2Glc]- Ginsenoside F2 (M3)
621[M-H-Glc]-, 459[M-H-2Glc]- Gypenoside LXXV (M4)
621[M-H-Glc]-, 459[M-H-2Glc]- Ginsenoside Rg3
459[M-H-Glc]- Ginsenoside Rh2
459[M-H-Glc]- Compound K (M5)
Table 2 Calibration curves of ginsenosides in simulated gastric fluid and an in vitro human gut bacteria incubation
system
Matrix Analyte Calibration curve (μΜ) r2 Concentration range (μΜ)
Simulated gastric fluid Rb1 Y = 3.504X + 6.912 0.9999 2.08-167.00
Rd Y = 3.796X-3.843 0.9999 11.30-3618.00
G-XVII Y = 3.549X-3.430 0.9999 5.21-1666.67
F2 Y = 3.339X-1.033 0.9999 5.21-1666.67
Rg3 Y = 3.377X + 10.180 0.9998 1.85-148.30
Cpd K Y = 3.807X + 0.303 0.9999 5.21-1666.67
Rh2 Y = 3.644X + 6.880 0.9999 5.21-1666.67
Human gut bacteria Rb1 Y = 6.1209X + 0.094 0.9986 50.00-800.00
Rd Y = 7.3891X + 4E-0.5 0.9998 31.25-500.00
G XVII Y = 6.1571X + 0.062 0.9999 30.00-200.00
F2 Y = 6.7242X + 0.003 0.9999 16.25-260.00
Cpd K Y = 6.7841X + 0.042 0.9945 5.16-165.00
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levels (representing ~7% of the initial Rb1). The amount of
Cpd K peaked at 36 h. Compared with their respective
positional isomers Rd and F2, G-XVII and G-LXXV
formed from the gypenoside pathway reached their
maximum levels more rapidly (Tmax: 4 and 8-12 h, re-
spectively). Because the positional isomers Rd and G-
XVII showed similar UV responses, as evidenced by the
very close constant coefficients (Table 2), we assumed
that F2 and G-LXXV, the positional isomers formed byFigure 2 Time-courses of the elimination and metabolite formations
line) in human gut bacteria.hydrolytic removal of two glucoses from C-3 and C-20
(F2) and C-3 (G-LXXV), would also have similar UV re-
sponses. Thus, the levels of the positional isomers F2
and G-LXXV were calculated using the calibration
curve of F2. Both gypenosides were formed at relatively
lower levels than their positional isomers. The max-
imum level of G-XVII was about 10% of Rd, while that
of G-LXXV was half of the peak concentration of F2.
Moreover, both gypenosides had disappeared from the
incubation system within 24 h, long before Cpd Kof (A) ginsenoside Rb1, and (B) Rd (solid line) and G-XVII (dotted
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were still detectable at 48 h. Thus, the gypenoside path-
way should be the minor pathway of Rb1 biotransform-
ation by human gut bacteria.
Biotransformation of Rd and G-XVII by human gut
bacteria
Rd and G-XVII were depleted within 8 h by human gut
bacteria, and generated F2 and Cpd K when incubated
separately. The generations of F2 and Cpd K from Rd
peaked at 2 and 12 h, respectively, while those generated
from G-XVII reached their maximum levels at 4 and
18 h, respectively. The maximum levels of F2 and Cpd K
formed from Rd were comparable to those from G-XVII
(about 30 and 80 μM, reflecting 30% and 80% of the
original amounts of the respective parent compounds)
(Figure 2B).Figure 3 Ginsenoside Rb1 metabolism and its metabolite formation b
different ages (B) and sexes (C).G-LXXV was also generated by human gut bacteria as
evidenced by the retention time and mass spectral pro-
file. F2 presented as a major metabolite and the Cmax
was two times higher that of G-LXXV (Figure 2B). There-
fore, both the G-XVII→ F2 and G-XVII→G-LXXV path-
ways of G-XVII metabolism existed in the human gut
bacteria, with the former as the major pathway in vitro.
Rb1 biotransformation by individual human gut bacterial
samples
When Rb1 was separately incubated with gut bacterial
samples from 58 individuals aged 18-92 years (30 females
and 28 males; range, 39.6-75.3 years), great inter-individual
variations were observed in terms of the remaining Rb1
and the amounts of metabolites formed via the Rd and
gypenoside pathways (Figure 3A). However, when com-
pared by age, there were no significant differences in Rb1y gut bacteria samples from 58 healthy individuals (A) of
Shen et al. Chinese Medicine 2013, 8:22 Page 8 of 11
http://www.cmjournal.org/content/8/1/22elimination and each pathway among individuals aged
18-45 years (20 individuals; range, 29.2-47 years), 46-
70 years (22 individuals; range, 52.7-65.9 years), and 71-
92 years (16 individuals; range, 72.6-85.4 years) (Figure 3B).
No sex differences (P values: 0.3 ~ 0.5) were observed in
Rb1 metabolism and each pathway by human gut bacteria
(Figure 3C).Degradation of Rb1 and Rd in SGF
The calibration curves of Rb1, Rd, G-XVII, F2, Rg3, Cpd
K, and Rh2 in SGF showed good linearity (r2 > 0.998,
P < 0.001) over the concentration ranges tested (Table 2).
Rb1 was rapidly degraded under acidic environments
to half of its original amount in 1 h, with <10% remaining
at 3 h (Figure 4). Ginsenosides F2, Rg3, Cpd K, and Rh2
were all detected in SGF. However, Rd was not detected
throughout the incubation period (Figure 4A). When Rd
was incubated in SGF, it was rapidly degraded to half its
initial amount in 2 h. The same products (F2, Rg3, Cpd K,
and Rh2) were generated. In both cases, F2 was the most
abundant product in SGF, and the gypenosides were not
detected (Figure 4A).
The in vitro bacterial biotransformation experiments
suggested the existence of metabolic pathways for Rb1
in human gut bacteria as follows: Rb1 lost one C-20Figure 4 HPLC-UV chromatograms (A) and degradation time-coursesglucose to generate Rd (major) and one C-3 glucose to
generate G-XVII (minor); Rd lost another C-20 glucose
to generate F2 and then one C-3 glucose to generate
Cpd K; G-XVII further lost one C-20 glucose to form F2
(major), one C-3 glucose to generate G-LXXV (minor),
or both; both were finally metabolized to Cpd K. How-
ever, under acidic conditions, the degradation of Rb1
was initiated by simultaneous loss of two glucose mole-
cules from both the C-3 and C-20 positions to generate
F2 (major) or Rg3 (minor). The metabolic pathway of
Rb1 in human gut bacteria shown in Figure 5A and the
degradation pathways of Rb1 and Rd in SGF shown in
Figure 5B were proposed for comparison.Discussion
Ginsenosides generally have poor oral bioavailability be-
cause of their low membrane permeability, active biliary
excretion, biotransformation, and so on [12]. Their de-
glycosylated products formed by bacterial conversion in
the gut lumen are more permeable and were demon-
strated to be bioactive [36]. As one of the main PPD-
type ginsenosides, ginsenoside Rb1 was deglycosylated
via Rb1→ Rd→ F2→ Cpd K (Rd pathway) [26,37]. An-
other pathway via Rb1→G-XVII→G-LXXV/F2→ Cpd
K has been reported in rats [24], single fungal strains(B) of Rb1 (solid line) and Rd (dotted line) in SGF.
Figure 5 Pathways of (A) Rb1 biotransformation by human intestinal microflora (→ major pathway; ⤏ minor pathway) and (B) Rb1
degradation in SGF.
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dobacterium longum sp. [38,39].
In this study with application of both LC-MS and LC-
DAD techniques, G-XVII and three metabolites (Rd, F2,
and Cpd K) were identified from the Rd pathway and G-
LXXV was tentatively assigned. The existence of both the
Rd and gypenoside pathways of Rb1 metabolism in human
gut bacteria was confirmed. The conversion of Rb1 to
Cpd K via both G-XVII→G-LXXV and G-XVII→ F2 was
also evidenced, for the first time, by the observation that
G-XVII produced G-LXXV, F2, and Cpd K, while Rd only
generated F2 and Cpd K, in human gut bacteria in vitro.
The gypenoside pathway was demonstrated to be the
minor pathway of Rb1 biotransformation in human gut
bacteria by comparing the maximum levels of Rd and F2
with those of their respective positional isomers G-XVII
and G-LXXV determined from a time-course study. More-
over, the maximum levels of the gypenoside products were
reached more rapidly than the products of the Rd pathway,
indicating that the gypenoside pathway was a transient
intermediate process. In contrast, the conversion rate of
Rd to Cpd K was faster than that of G-XVII to Cpd K, asjudged by the times required to reach the maximum level
of Cpd K when Rd and G-XVII were separately incubated
with human gut bacteria. These findings suggested that the
removal of the remote glucose molecule at the C-20 pos-
ition by human gut bacteria was faster than that of the
glucose molecule from the C-3 position, while further
cleavage of the second glucose from the C-3 position is a
much more difficult process, leading to the formation of
F2 much more rapidly than the formation of G-LXXV
from G-XVII. Eubacterium sp., Streptococcus sp., and Bifi-
dobacterium sp., which were more potent in hydrolyzing
gentiobiose than sophorose, metabolized Rb1 to Cpd K via
Rd rather than G-XVII [39]. However, Fusobacterium K-60,
which hydrolyzed sophorose more potently than gentio-
biose, metabolized Rb1 to Cpd K via G-XVII. Bifidobac-
teria are probiotics and belong to the predominant gut
bacteria, while streptococci and fusobacteria are patho-
genic bacteria and are in the minority in healthy humans
[40]. This may explain why the Rd pathway was the
major pathway, while the gypenoside pathway was the
minor pathway of Rb1 in human gut bacteria from
healthy volunteers.
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in SGF and its products including F2, Rg3, Cpd K, and
Rh2 were detected, consistent with the findings ob-
tained from previous in vitro [41] and in vivo [42] stud-
ies. Rd yielded the same four products in SGF. However,
gypenosides were not detected in SGF in both cases, in-
dicating that when Rb1 is taken orally, gypenosides may
only be formed through bacterial biotransformation in
the gut lumen.
Great inter-individual variations in Rb1 metabolism by
human gut bacteria were observed with both the gypeno-
side and Rd pathways owing to the great individual varia-
tions in the species and amounts of the gut bacteria. These
variations showed no differences between sexes and ages.
Thus far, only the Rd pathway has been reported
in vivo in the human body [25,26]. The minor amount
of gypenosides formed by the human gut bacteria may
provide beneficial effects for the human body. Thus, fur-
ther studies are warranted to evaluate the contributions
of these gypenosides to the health-promoting effects of
ginsenoside Rb1 in vivo.
Conclusions
Rb1 was metabolized to G-XVII, F2 (major) or G-LXXL
(minor), and finally Cpd K by human gut bacteria in vitro.
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